Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes.
about
Glucagon and heart in type 2 diabetes: new perspectivesRegulation of Chemokine Activity - A Focus on the Role of Dipeptidyl Peptidase IV/CD26Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes.DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus.Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.Tofogliflozin decreases body fat mass and improves peripheral insulin resistance.Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study.
P2860
Q26738580-3AB7AF34-FEAA-4C5D-B7F0-7AB0B7CB2205Q28072580-5C44C5EC-7959-4C39-B3D1-5432A472CCAEQ33835558-E815E5FC-FA57-45DB-823E-C7B9FC3C8D1CQ38856808-58FD0454-16DC-4D8B-B46F-49A63385D24BQ38902321-B1F1779F-DED7-42E0-91BA-282E5FE5B9ADQ39063447-5B1771AC-9C20-4101-A175-48858DDB35E0Q43162911-2084D67C-8AFE-44D1-89B1-4825CDF666B6Q47148933-E05D870D-1F4B-46A6-8133-27CE14DB0FC5Q47687852-530B1E08-2731-4D4D-9694-8C87CB2E3A53Q48279832-93EA4167-A924-4FD5-BD88-9AB5E6C35ED5Q51240449-F2DCFEA3-F054-4D46-B9EC-9A0A28DEFD85
P2860
Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Potential for combination of d ...... treatment of type 2 diabetes.
@ast
Potential for combination of d ...... treatment of type 2 diabetes.
@en
type
label
Potential for combination of d ...... treatment of type 2 diabetes.
@ast
Potential for combination of d ...... treatment of type 2 diabetes.
@en
prefLabel
Potential for combination of d ...... treatment of type 2 diabetes.
@ast
Potential for combination of d ...... treatment of type 2 diabetes.
@en
P2860
P921
P356
P1476
Potential for combination of d ...... treatment of type 2 diabetes.
@en
P2093
M D Sharma
P2860
P304
P356
10.1111/DOM.12451
P5008
P577
2015-03-22T00:00:00Z
2015-07-01T00:00:00Z